| abstract |
The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular, the construct comprises a fusion between a heat shock protein gene HSP70, typically from Mycobacterium tuberculosis and MUCl-1 or derivative thereof. The invention further provides pharmaceutical compositions comprising said constructs and proteins, particularly pharmaceutical compositions adapted for particle mediated delivery, methods for producing them, and their use in medicine, particularly in the treatment of MUCl-1 expressing tumours. |